| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/23/2007 | US7166594 Streptogramin derivatives, their preparation and compositions containing them |
| 01/23/2007 | US7166593 Glucocorticoid receptor modulators |
| 01/23/2007 | US7166592 Antiinflammatory agents |
| 01/23/2007 | US7166591 Catalytic cleavage of phosphate ester bonds by boron chelates |
| 01/23/2007 | US7166590 Antiischemic agents; cardiovascular disorders |
| 01/23/2007 | US7166589 Quinoline derivatives |
| 01/23/2007 | US7166588 Derivatives and analogs of galanthamine |
| 01/23/2007 | US7166587 Gamma -secretase inhibitors; for treatment of Alzheimer's disease; e.g 2,3-difluoro-benzyl)-carbamic acid (S)-1-(5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-ylcarbamoyl)-ethyl ester |
| 01/23/2007 | US7166586 Sulfonamide lactam inhibitors of FXa and method |
| 01/23/2007 | US7166585 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3 |
| 01/23/2007 | US7166584 Administering glyburide to intestinal lumen of animals; inhibits transport of cholesterol to the bloodstream; modulates the activity of ATP- binding cassette (ABC1) protein |
| 01/23/2007 | US7166583 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 01/23/2007 | US7166582 Administering stachyose to treat atopic dermatitis; can be added to medicine, food and beverage |
| 01/23/2007 | US7166581 Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| 01/23/2007 | US7166570 Treating varicose or veins by injecting a composition silk made of polyalkylene oxide-polyester block copolymer into the lumen of a vein; anchoring implantable medical devices into or onto biological tissue |
| 01/23/2007 | US7166472 Adding a reducible redox-active metal to a first and a second target protein sample of an auto-oxidizing kynurenine pathway metabolite; incubating to allow cross-linking of target protein, comparing the amounnt of target protein cross-linking |
| 01/23/2007 | US7166467 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis |
| 01/23/2007 | US7166455 A genetic engineered nuclear acids, culturing Bacteroides fragilis, encoding immunomodulator, treating inflammatory bowel disease |
| 01/23/2007 | US7166450 Hyaluronan synthase gene and uses thereof |
| 01/23/2007 | US7166438 In Vitro screening for ligands of the estrogen receptor |
| 01/23/2007 | US7166433 Purified nucleic acids encoding transmembrane cochlear-expressed genes; prognosticating and monitoring hearing loss; vectors, cell lines, monoclonal antibodies; genetic engineering |
| 01/23/2007 | US7166310 Stable extract from Hypericum perforatum L., method for the production thereof and its use as a topical medicament |
| 01/23/2007 | US7166309 Nutritional composition and method of inhibiting smooth muscle cell contraction thereof |
| 01/23/2007 | US7166308 Treatment of Alzheimer's disease (AD) and senile dementia of the Alzheimer's type (SDAT) |
| 01/23/2007 | US7166305 granules of starch which have been expanded or preswelled and crosslinked, followed by reaction with a polyvalent Ca, Mg, Zn Cu, or Al metal salt; |
| 01/23/2007 | US7166303 An aqueous solution comprising of propofol, poloxamers; noncontamination, stability |
| 01/23/2007 | US7166302 Complexing agents for compositions containing inclusion complexes |
| 01/23/2007 | US7166301 Immediate release medicinal compositions for oral use |
| 01/23/2007 | US7166299 Comprises ursodeoxycholic acid for treating gastritis and peptic ulcer disease |
| 01/23/2007 | US7166298 Genetic immunization with cationic lipids |
| 01/23/2007 | US7166297 Comprises liposomes attached to prodrugs through phosphonate linkages; phospholipases; targets liver/spleen |
| 01/23/2007 | US7166293 Anticancer agents; antitumor agents; cardiovascular diosrders; antiinflammatory agents |
| 01/23/2007 | US7166287 Viral agent |
| 01/23/2007 | US7166286 Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for prophylaxis and detection of cancers |
| 01/23/2007 | US7166283 Bind to AILIM (activation inducible lymphocyte immunomodulatory molecule, also referred to as ICOS (inducible co-stimulator); human monoclonal antibodies which bind to AILIM or a portion thereof; for treating disorders related to the delayed allergy |
| 01/23/2007 | CA2456970C Drug formulations for parenteral use |
| 01/23/2007 | CA2378918C Method of treating symptoms of hormonal variation, including hot flashes |
| 01/23/2007 | CA2348086C Controlled-release pharmaceutical formulations |
| 01/23/2007 | CA2345466C Sustained release, and comfortable ophthalmic composition and method for ocular therapy |
| 01/23/2007 | CA2340427C Non-sedating diphenhydramine metabolites |
| 01/23/2007 | CA2338311C Prodrugs of the pyridyl methyl sulfinyl benzimidazoles |
| 01/23/2007 | CA2332188C 5-(1-aminocyclohexyl)-2(1h)-pyridinone compounds and intermediates in the production thereof |
| 01/23/2007 | CA2331288C Aqueous process for manufacturing paroxetine solid dispersions |
| 01/23/2007 | CA2329193C Process for synthesizing cox-2 inhibitors |
| 01/23/2007 | CA2326389C Novel cd19xcd3 specific polypeptides and uses thereof |
| 01/23/2007 | CA2289753C Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
| 01/23/2007 | CA2288045C A new class of benzoporphyrin derivative photoactive compounds |
| 01/23/2007 | CA2269946C Naphthyridine derivatives |
| 01/23/2007 | CA2266519C Pyrimidine derivatives and processes for the preparation thereof |
| 01/23/2007 | CA2260037C Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| 01/23/2007 | CA2245804C Recombinant ribonuclease proteins |
| 01/23/2007 | CA2239968C Pyrimidine derivatives and guanine derivatives, and their use in treating tumour cells |
| 01/23/2007 | CA2237571C A glibenclamide-metformin combination for the treatment of diabetes mellitus of type ii |
| 01/23/2007 | CA2231879C Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same |
| 01/23/2007 | CA2216169C Use of compositions comprising stabilized biologically effective compounds |
| 01/23/2007 | CA2211400C Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin |
| 01/23/2007 | CA2208495C The preparation of salts of pharmaceutical active substances which have acidic groups |
| 01/23/2007 | CA2206754C Benzimidazole derivatives with antihistaminic activity |
| 01/23/2007 | CA2191747C (a)-annelated pyrrole derivatives and pharmaceutical use thereof |
| 01/23/2007 | CA2176603C Novel palladium complexes and methods for using same in the treatment of tumors and psoriasis |
| 01/23/2007 | CA2164296C Heterocyclic chemistry |
| 01/23/2007 | CA2107400C Method of grinding pharmaceutical substances |
| 01/23/2007 | CA2101104C Amino acid linked nitrogen mustard derivatives and their use as prodrugs in the treatment of tumors |
| 01/19/2007 | CA2552059A1 Products for topical application comprising lysophospholipids and fatty acids |
| 01/18/2007 | WO2007009109A2 Antiviral compounds |
| 01/18/2007 | WO2007009101A2 Tetraazaporphyrin-based compounds and their uses |
| 01/18/2007 | WO2007009092A2 Method for improved accuracy of blood testing |
| 01/18/2007 | WO2007009055A2 Ester prodrugs of prostratin and related phorbol compounds |
| 01/18/2007 | WO2007009044A2 Inhibitors of egln3 activity for the treatment of neurodegenerative disorders |
| 01/18/2007 | WO2007009001A1 Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to alleviate eye disorders |
| 01/18/2007 | WO2007008985A2 Kinase inhibitors |
| 01/18/2007 | WO2007008963A1 Mao-b inhibitors useful for treating obesity |
| 01/18/2007 | WO2007008927A2 Bioresorbable composition for repairing skeletal tissue |
| 01/18/2007 | WO2007008926A1 Isoquinoline compounds |
| 01/18/2007 | WO2007008907A2 Methods for determining how to treat congestive heart failure |
| 01/18/2007 | WO2007008895A1 Kinase inhibitors |
| 01/18/2007 | WO2007008869A1 Methods of dosing propofol prodrugs for inducing mild to moderate levels of sedation |
| 01/18/2007 | WO2007008858A2 Metered-dose and safety and compliance packaging for systemic anticancer therapy |
| 01/18/2007 | WO2007008821A2 Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (rbp), and/or serum retinol-rbp modulation |
| 01/18/2007 | WO2007008810A2 Method for reducing blood loss associated with cardio-pulmonary bypass surgery |
| 01/18/2007 | WO2007008752A2 Sustained release pharmaceutical compositions for highly water soluble drugs |
| 01/18/2007 | WO2007008691A2 Use of microchimeric cells in the treatment of malignancy |
| 01/18/2007 | WO2007008674A1 Crystalline cefdinir hydrates |
| 01/18/2007 | WO2007008673A2 Crystalline anhydrous cefdinir and crystalline cefdinir hydrates |
| 01/18/2007 | WO2007008672A1 Crystalline cefdinir trihemihydrate |
| 01/18/2007 | WO2007008665A1 Composition and the use thereof for the treatment of viral infections |
| 01/18/2007 | WO2007008664A1 3-spir0cycl0pr0pyl2-0xind0le kinase inhibitors |
| 01/18/2007 | WO2007008627A2 Apoptosis promoters |
| 01/18/2007 | WO2007008588A2 Omeprazole form b |
| 01/18/2007 | WO2007008586A2 Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions |
| 01/18/2007 | WO2007008576A2 Oxcarbazepine formulation |
| 01/18/2007 | WO2007008548A2 Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| 01/18/2007 | WO2007008514A2 Inhibitors of glycogen synthase kinase 3 |
| 01/18/2007 | WO2007008502A2 Inhibitors of checkpoint kinases |
| 01/18/2007 | WO2007008501A1 Antidiabetic oxazolidinediones and thiazolidinediones |
| 01/18/2007 | WO2007008496A1 Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
| 01/18/2007 | WO2007008490A2 Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| 01/18/2007 | WO2007008474A2 3 -ester prodrugs of estradiol |
| 01/18/2007 | WO2007008427A2 Aerosol compositions and methods |
| 01/18/2007 | WO2007008350A1 Pharmaceutical formulations of endo-n-(9- methyl-9-azabicyclo[3 .3.1]non-3-yl)-1-methyl-1h-indazole-3-carboxamide hydrochloride |